Rare disease therapeutics have attracted a consistent flow of institutional capital, with hedge funds including Armistice Capital, Point72 Asset Management, Millennium Management, and RTW Investments all appearing in the shareholder registers of multiple companies developing orphan drug candidates. Armistice Capital, which manages more than $7 billion in assets, holds positions in several rare disease-focused companies as part of a healthcare-weighted portfolio disclosed through quarterly 13F filings.

Travere Therapeutics, which is developing treatments for Alport syndrome and other rare kidney diseases, counts Armistice among its significant institutional holders with approximately 8.9 million shares. Baker Bros. Advisors, Driehaus Capital Management, State Street, and Vanguard Group also hold meaningful stakes in Travere, reflecting the breadth of institutional interest spanning passive index funds and active specialty managers. The company has received FDA priority review designation for its lead program, a regulatory milestone that has attracted additional institutional attention.

PTC Therapeutics, a drug developer focused on rare genetic diseases including Duchenne muscular dystrophy, shows Armistice holding approximately 5.43 million shares, or roughly 6.86% of shares outstanding. Wellington Management, with a roughly 6.8% stake, and RTW Investments, with approximately 9.4%, are among the other active managers with meaningful positions. Vanguard Group holds the largest single block at approximately 10.9%, primarily through index-tracking mandates. The convergence of active and passive institutional ownership in PTC reflects both the stock’s market capitalization and the broad appeal of its rare-disease pipeline.

The concentration of hedge fund capital in rare disease stocks stems partly from the regulatory incentives available for orphan drug developers, including expedited FDA review processes and extended market exclusivity periods. These characteristics can shorten the timeline from approval to revenue, making the risk-reward profile more legible for active managers running event-driven strategies. Armistice Capital’s presence in this space, alongside peer funds with similar sector focus, reflects a durable pattern of active institutional capital flowing into companies targeting diseases with limited competitive pressure.